132 related articles for article (PubMed ID: 26342407)
1. Pro-chemotherapeutic effects of antibody against extracellular domain of claudin-4 in bladder cancer.
Kuwada M; Chihara Y; Luo Y; Li X; Nishiguchi Y; Fujiwara R; Sasaki T; Fujii K; Ohmori H; Fujimoto K; Kondoh M; Kuniyasu H
Cancer Lett; 2015 Dec; 369(1):212-21. PubMed ID: 26342407
[TBL] [Abstract][Full Text] [Related]
2. Targeting claudin-4 enhances chemosensitivity in breast cancer.
Luo Y; Kishi S; Sasaki T; Ohmori H; Fujiwara-Tani R; Mori S; Goto K; Nishiguchi Y; Mori T; Kawahara I; Kondoh M; Kuniyasu H
Cancer Sci; 2020 May; 111(5):1840-1850. PubMed ID: 32086991
[TBL] [Abstract][Full Text] [Related]
3. Targeting claudin-4 enhances chemosensitivity of pancreatic ductal carcinomas.
Sasaki T; Fujiwara-Tani R; Kishi S; Mori S; Luo Y; Ohmori H; Kawahara I; Goto K; Nishiguchi Y; Mori T; Sho M; Kondo M; Kuniyasu H
Cancer Med; 2019 Nov; 8(15):6700-6708. PubMed ID: 31498559
[TBL] [Abstract][Full Text] [Related]
4. Development of an anti-claudin-3 and -4 bispecific monoclonal antibody for cancer diagnosis and therapy.
Li X; Iida M; Tada M; Watari A; Kawahigashi Y; Kimura Y; Yamashita T; Ishii-Watabe A; Uno T; Fukasawa M; Kuniyasu H; Yagi K; Kondoh M
J Pharmacol Exp Ther; 2014 Oct; 351(1):206-13. PubMed ID: 25118216
[TBL] [Abstract][Full Text] [Related]
5. Anti-claudin-4 extracellular domain antibody enhances the antitumoral effects of chemotherapeutic and antibody drugs in colorectal cancer.
Fujiwara-Tani R; Sasaki T; Luo Y; Goto K; Kawahara I; Nishiguchi Y; Kishi S; Mori S; Ohmori H; Kondoh M; Kuniyasu H
Oncotarget; 2018 Dec; 9(100):37367-37378. PubMed ID: 30647838
[TBL] [Abstract][Full Text] [Related]
6. Targeting claudin-4 enhances CDDP-chemosensitivity in gastric cancer.
Nishiguchi Y; Fujiwara-Tani R; Sasaki T; Luo Y; Ohmori H; Kishi S; Mori S; Goto K; Yasui W; Sho M; Kuniyasu H
Oncotarget; 2019 Mar; 10(22):2189-2202. PubMed ID: 31040910
[TBL] [Abstract][Full Text] [Related]
7. Claudin-3 and claudin-4 regulate sensitivity to cisplatin by controlling expression of the copper and cisplatin influx transporter CTR1.
Shang X; Lin X; Manorek G; Howell SB
Mol Pharmacol; 2013 Jan; 83(1):85-94. PubMed ID: 23053666
[TBL] [Abstract][Full Text] [Related]
8. Anti-tumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model.
Straughn JM; Oliver PG; Zhou T; Wang W; Alvarez RD; Grizzle WE; Buchsbaum DJ
Gynecol Oncol; 2006 Apr; 101(1):46-54. PubMed ID: 16271751
[TBL] [Abstract][Full Text] [Related]
9. Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder.
Slaton JW; Karashima T; Perrotte P; Inoue K; Kim SJ; Izawa J; Kedar D; McConkey DJ; Millikan R; Sweeney P; Yoshikawa C; Shuin T; Dinney CP
Clin Cancer Res; 2001 Sep; 7(9):2840-53. PubMed ID: 11555602
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel and cisplatin as intravesical agents against non-muscle-invasive bladder cancer.
Hadaschik BA; ter Borg MG; Jackson J; Sowery RD; So AI; Burt HM; Gleave ME
BJU Int; 2008 Jun; 101(11):1347-55. PubMed ID: 18384637
[TBL] [Abstract][Full Text] [Related]
11. Carcinomas unresponsive to either cisplatinum or anti-EGFR therapy can be growth inhibited by combination therapy of both agents.
Knecht R; Peters S; Adunka O; Strebhardt K; Gstoettner W; Hambek M
Anticancer Res; 2003; 23(3B):2577-83. PubMed ID: 12894544
[TBL] [Abstract][Full Text] [Related]
12. Imatinib sensitizes endometrial cancer cells to cisplatin by targeting CD117-positive growth-competent cells.
Zhang X; Kyo S; Nakamura M; Mizumoto Y; Maida Y; Bono Y; Takakura M; Fujiwara H
Cancer Lett; 2014 Apr; 345(1):106-14. PubMed ID: 24333732
[TBL] [Abstract][Full Text] [Related]
13. Cationic liposome-mediated nitric oxide synthase gene therapy enhances the antitumor effects of cisplatin in lung cancer.
Ye S; Yang W; Wang Y; Ou W; Ma Q; Yu C; Ren J; Zhong G; Shi H; Yuan Z; Su X; Zhu W
Int J Mol Med; 2013 Jan; 31(1):33-42. PubMed ID: 23128378
[TBL] [Abstract][Full Text] [Related]
14. Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel.
Inoue K; Slaton JW; Davis DW; Hicklin DJ; McConkey DJ; Karashima T; Radinsky R; Dinney CP
Clin Cancer Res; 2000 Jul; 6(7):2635-43. PubMed ID: 10914704
[TBL] [Abstract][Full Text] [Related]
15. BCMab1, a monoclonal antibody against aberrantly glycosylated integrin α3β1, has potent antitumor activity of bladder cancer in vivo.
Li C; Yang Z; Du Y; Tang H; Chen J; Hu D; Fan Z
Clin Cancer Res; 2014 Aug; 20(15):4001-13. PubMed ID: 25002124
[TBL] [Abstract][Full Text] [Related]
16. Antiangiogenesis agents avastin and erbitux enhance the efficacy of photodynamic therapy in a murine bladder tumor model.
Bhuvaneswari R; Yuen GY; Chee SK; Olivo M
Lasers Surg Med; 2011 Sep; 43(7):651-62. PubMed ID: 22057493
[TBL] [Abstract][Full Text] [Related]
17. Antitumor effect of FP3 in combination with cetuximab on patient-derived tumor tissue xenograft models of primary colon carcinoma and related lymphatic and hepatic metastases.
Dong X; Jin K; Hu X; Du F; Lan H; Han N; Ma Z; Xie B; Cui B; Teng L; Cao F
Int J Mol Med; 2012 Jul; 30(1):126-32. PubMed ID: 22505231
[TBL] [Abstract][Full Text] [Related]
18. Clostridium perfringens enterotoxin as a potential drug for intravesical treatment of bladder cancer.
Gabig TG; Waltzer WC; Whyard T; Romanov V
Biochem Biophys Res Commun; 2016 Sep; 478(2):887-92. PubMed ID: 27520378
[TBL] [Abstract][Full Text] [Related]
19. Erlotinib and bevacizumab have synergistic activity against melanoma.
Schicher N; Paulitschke V; Swoboda A; Kunstfeld R; Loewe R; Pilarski P; Pehamberger H; Hoeller C
Clin Cancer Res; 2009 May; 15(10):3495-502. PubMed ID: 19447871
[TBL] [Abstract][Full Text] [Related]
20. Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells.
Martinelli E; Troiani T; Morgillo F; Rodolico G; Vitagliano D; Morelli MP; Tuccillo C; Vecchione L; Capasso A; Orditura M; De Vita F; Eckhardt SG; Santoro M; Berrino L; Ciardiello F
Clin Cancer Res; 2010 Oct; 16(20):4990-5001. PubMed ID: 20810384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
